Strona zrobiona w kreatorze stron internetowych WebWave

Europejskie Centrum Bioinformatyki i Genomiki

Instytut Informatyki Politechniki Poznańskiej

Wielkopolskie Centrum Zaawansowanych Technologii

Institute of Bioorganic Chemistry,
Polish Academy of Sciences
Z. Noskowskiego 12/14
61-704 Poznań
tel centrala: (+48) 61 852 85 03
fax: (+48) 61 852 05 32
e-mail: ibch@ibch.poznan.pl

Sekretariat Dyrektora, tel: 61 852 89 19

Department of Genome Engineering

Dr. habil. Marta Olejniczak

Head of Department
marta.olejniczak@ibch.poznan.pl
ext. wew. 1136

Anna Kotowska-Zimmer MSc

PhD student

Marianna Pewińska MSc

biologist

Mateusz Nowaczyk MSc

PhD student

Magdalena Dąbrowska MSc

PhD student

Marianna Karwacka
magistrant

Anna Misiukiewicz MSc

biologist

Teresa Dymarek-Babś MSc

starszy specjalista biolog

Dr. Paweł Śledziński
adiunkt

• Kotowska-Zimmer A, Pewinska M and Olejniczak M*, Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdiscip Rev RNA 2021; e1640

• Sledzinski P, Nowaczyk M and Olejniczak M*, Computational Tools and Resources Supporting CRISPR-Cas Experiments. Cells. 2020, 9, 1288

• Dabrowska M, Ciolak A, Kozlowska E, Fiszer A and Olejniczak M*, Generation of New Isogenic Models of Huntington’s Disease Using CRISPR-Cas9 Technology. Int  J Mol Sci. 2020, 21, 1854 

• Kotowska-Zimmer A, Ostrovska Y and Olejniczak M*. Universal RNAi triggers for the specific inhibition of mutant huntingtin, atrophin-1, ataxin-3 and ataxin-7 expression. Mol Ther Nucl Acids 2020, 19:562-571.

• Dabrowska M, and Olejniczak M*, Gene therapy for Huntington's disease using targeted endonucleases. Methods Mol Biol. 2020, 2056:269-284

• Dabrowska M, Czubak K, Juzwa W, Krzyzosiak WJ, Olejniczak M*, Kozlowski P*. qEva-CRISPR: a method for quantitative evaluation of CRISPR/Cas-mediated genome editing in target and off-target sites. Nucleic Acids Res. 2018, 46:e101

• Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M* Precise excision of the CAG tract from the Huntingtin Gene by Cas9 Nickases, Front Neurosci. 2018, 12:75 

• Olejniczak M*, Kotowska-Zimmer A, Krzyzosiak WJ. Stress-induced changes in miRNA biogenesis and functioning, Cell Mol Life Sci., 2018, 75:177-191

• Olejniczak M*, Urbanek M.O., Jaworska E, Witucki Ł, Szcześniak M.W., Makałowska I, Krzyzosiak WJ.  Sequence-non-specific effects generated by various types of RNA interference triggers. BBA Gene Regul Mech. 2016, 1859:306-14

• Olejniczak M*, Urbanek MU, Krzyzosiak WJ* The Role of the Immune System in Triplet Repeat Expansion Diseases. Mediators Inflamm. 2015, 873860, 

• Olejniczak M, Galka-Marciniak P, Polak K, Fligier A, Krzyzosiak WJ. RNAimmuno: A database of the nonspecific immunological effects of RNA interference and microRNA reagents. RNA 2012, 18:930-5

• Olejniczak M,  Polak K, Galka-Marciniak P, Krzyzosiak WJ. Recent advances in understanding of the immunological off-target  effects of siRNA.  Curr  Gene Ther. 2011, 17

• Olejniczak M, Galka P, Krzyzosiak WJ. Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res. 2010, 38: 1-16.

• NCN, SONATA BIS - The use of genetic tools in the experimental therapy of polyglutamine diseases

• NCN, OPUS - Investigation of DNA double-strand break repair mechanisms in microsatellite regions using the CRISPR-Cas9 system

• NCN, PRELUDIUM BIS - Allele-selective therapy for polyglutamine diseases with the use of RNA interference technology

• NCN, ETIUDA – The use of genome editing systems in experimental therapy for polyglutamine disorders

• genome editing,
• CRISPR/Cas9,
• Cpf1,
• genetic therapy,
• RNA interference,
• miRNA,
• Huntington’s disease

Research in the Department of Genome Engineering is currently focused on three major areas:

• Development of genome editing technologies and methods for assessing its effectiveness and specificity

• The use of genome editing technology to establish disease models and in cell and pre-clinical therapy of genetic diseases 

• The use of genetic tools in experimental therapy for polyglutamine diseases